Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist-Reference-Cited by-同舟云学术

Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist

Published:2006-02-09 Issue:2 Volume:317 Page:910-918
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Vanover Kimberly E.,Weiner David M.,Makhay Malath,Veinbergs Isaac,Gardell Luis R.,Lameh Jelveh,Del Tredici Andria L.,Piu Fabrice,Schiffer Hans H.,Ott Thomas R.,Burstein Ethan S.,Uldam Allan K.,Thygesen Mikkel B.,Schlienger Nathalie,Andersson Carl Magnus,Son Thomas Y.,Harvey Scott C.,Powell Susan B.,Geyer Mark A.,Tolf Bo-Ragner,Brann Mark R.,Davis Robert E.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference35 articles.

1. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease

2. Regulation of serotonin-2C receptor G-protein coupling by RNA editing

3. Prestimulus Effects on Human Startle Reflex in Normals and Schizophrenics

4. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites

Cited by 190 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imaging the 5-HT_2C receptor with PET: Evaluation of 5-HT_2C and 5-HT_2A affinity of pimavanserin in the primate brain;Journal of Cerebral Blood Flow & Metabolism;2024-08-21

2. Dual 5-HT_2A and 5-HT_2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis;Journal of Medicinal Chemistry;2024-08-13

3. Review of Current Clinical Options for the Management of Behavioral and Psychological Symptoms of Dementia;The Senior Care Pharmacist;2024-08-01

4. Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments;Pharmacopsychiatry;2024-05-06

5. New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction;Biological Psychiatry;2024-05